-
Most Recent
Search Results
240 results for HGSI
HGSI Holdout Proves Profitable — for Bagels
Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.
Human Genome Sciences (HGSI) – What’s Ahead After Positive Lupus Study?
Human Genome Sciences (HGSI) stock soared after news that Benlysta, its drug for lupus, met primary endpoints. What’s ahead for HGSI?
Cue the Biotech M&A Attack!
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.
3 Wall Street Deals That Fizzled in Q2
Three companies targeted for buyouts still haven’t (or declined to) pull the trigger in Q2, leaving shareholders wondering whether management did right by them.
GlaxoSmithKline to Pay $3.6B for Human Genome Sciences
GlaxoSmithKline will pay $14.25 a share, a total of $3.6 billion, to acquire its long-term research partner Human Genome Sciences.
9 Biotech Buyout Players to Watch
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts — and these biotech players could be next.
9 Market-Moving Stocks to Watch This Week (HGSI, MBI, SPLS, TECD, PAY, BJS, COST, CIEN, SPWRA)
Key market-moving earnings reports to watch this week include Human Genome Science (HSSI), Staples (SPLS), Verifone (PAY), BJ’s Wholesale (BJS), Costco (COST) and Sunpower Corp.…
Ups and Downs the Norm — Thursday’s IP Market Recap
Markets went on a roller-coaster ride again today, starting with an early move up and coming down the remainder of the day on disappointing economic…
In Case You Missed Wednesday
Stocks don’t take advantage of lower oil.
Youku-Tudou Hullabaloo! — Monday’s IP Market Recap
A big online video deal in China captured lots of attention today.
Solar Stocks Flare Up — Wednesday’s IP Market Recap
Two pieces of positive news send JinkoSolar, First Solar and other solar stocks skyward Wednesday after months of battering throughout the sector.
Banking on Buyouts in Biotech: Is It Smart?
Unless you really understand medicine, it’s a very risky game. The chances of a little company scoring big and getting bought out are usually slim.
Comcast (CMCSA) to Give NBC New Home
Comcast (CMCSA) is closer to gaining ownership of NBC Universal from GE. But other companies in the industry like Time Warner (TWX) have learned that…
Don’t Get Sucked Into Overpriced InterMune Options
We’re seeing InterMune’s (ITMN) option prices being bid up on an FDA review date being set for the company’s drug, but the risk here is…
A Good Day or a Bad Day — It All Depends
Human Genome Sciences and eBay were among the big winners in the market on Thursday on a takeover bid and good earnings. As for some…
3 High-Flying ETFs That Still Look Good
These three are among the best-performing funds so far this year and, comparatively speaking, look to hold their own at least in the short term.
My Favorite Sector for Summer: Biotech
Stocks can suck in the summertime, but not every sector is doomed: Here’s why biotech could be the season’s sweetheart, and which stocks look hot.
1 – 10 of 240 results
